27558 Obeticholic acid (OCALIVA ®) protects against 2,8-dihydroxyadenine nephropathy in mice

27558 Obeticholic acid (OCALIVA ®) protects against 2,8-dihydroxyadenine nephropathy in mice

ABSTRACT IMPACT: This work may lead to new treatments for crystalline nephropathies. OBJECTIVES/GOALS: This study investigated obeticholic acid (OCALIVA ®) as a potential treatment for 2,8-dihydroxyadenine (2,8-DHA) nephropathy using a mouse model. The treatment was investigated in both sexes at two...

Full description

Bibliographic Details
Main Authors: Bryce Jones, Carlos Benitez, Idalia Cruz, Komuraiah Myakala, Xiaoxin Wang, Andrew Libby, Emma Rowland, Ryan Kurtz, Avi Rosenberg, Moshe Levi
Format: Article
Language:English
Published: Cambridge University Press 2021-03-01
Series:Journal of Clinical and Translational Science
Online Access:https://www.cambridge.org/core/product/identifier/S2059866121004283/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S2059866121004283/type/journal_article

Similar Items